secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2021-09-29T23:59:59+00:00
Accession:  0001193125-21-286070
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences reports improved pulmonary function in DMD gene therapy trial, controls decline
--------------------------------------------------------------------------------

- PEF % predicted improved in all 4 evaluable dosed patients (+2.5% to +38.5%); 2 evaluable controls declined (-1.1%, -18.2%) at one year.
- FEV1 % predicted improved in all 5 evaluable dosed patients (+2.8% to +15.5%); all 3 evaluable controls declined (-8.7% to -17.0%).
- Data from first 6 patients in Phase I/II IGNITE DMD trial of SGT-001; presented at Child Neurology Society 50th Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312521286070/0001193125-21-286070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312521286070/d230511d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-286070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer